Manyata Tech Park ( Call Girls ) Bangalore â 6297143586 â Hot Model With Sexy...
Â
ROLE OF RADIATION IN BONE TUMORS FOR ORTHOPEDICS
1. Dr. Kanhu Charan Patro
M.D,D.N.B[RT],P.D.C.R,C.E.P.C
[EX â TATA MEMORIAL HOSPITAL]
Consultant- Radiation Oncology
MAHATMA GANDHI CANCER HOSPITAL
VISAKHAPATNAM
Email-drkcpatro@gmail.com ,M-09160470564
2. ďNo one denies the importance of evidence.
It is a sine qua non of professional practice. But
often, there are no simple answers to
apparently simple questions: there is a role for
judgement and decision-making
3. Levels of evidence
ďLevel-I=large double blind RCTs, or, metaanalysis of
smaller RCTs , with clinically relevant outcomes
I a=evidence from meta-analysis of RCT
I b=evidence from at least 1 RCT
ďLevel-II=small RCTs, non-blinded RCTs
IIa=evidence from one well designed non-RCT
IIb=evidence from one well-designed quasi-
experimental study
ďLevel-III=observational [cohort ] studies ,case-
control studies , non-RCTs
ďLevel-IV=opinion of expert committees, or
respected authorities
ďLevel -V=expert opinion 3
12. GOALS
ďHigh dose to tumor tissue-Tumor control
ďNormal tissue sparing
ďMinimize long and short term toxicities
ďBetter Quality of life
10/20/12 01:12 PM 12
13. Evolution of Treatment Techniques
CONVENTIONAL RT
Collimator shapes Beam
Rectangular Treatment Field
Shaped Treatment Field
1970s and earlier
10/20/12 01:12 PM 13
18. Biopsy should be regarded as the
final diagnostic procedure, and not
a shortcut to diagnosis.
History
Imaging
Investgtn.
19. Biopsy should be regarded as the
final diagnostic procedure, and not
a shortcut to diagnosis.
âThe gross anatomy, as evidenced by X-rays is a
safer guide to a correct clinical conception of the
disease than the variable and uncertain structure of
the small piece of tissue sent for microscopyâ
Dr. James Ewing -1922
History
Imaging
Investgtn.
20. The biopsy should be performed by the
surgeon who will be doing the definitive
surgery
24. Needle Biopsy
ďOPD procedure, LA
ďCan be image guided or CT guided
ďPractically no infection
ďVery little tissue contamination
ďMuch smaller risk of causing fracture
ďCores from depth of the tumor
Minimally invasive, much less traumatic
25. ďMay not yield adequate tissue
ďMay be difficult to make a diagnosis
ďExperienced pathologist required to
be able to give a diagnosis on small
quantity of tissue
Needle Biopsy
28. Typical treatment
pathways in
osteosarcoma and
Ewingâs sarcoma,
illustrating their
similarities and
differences from
diagnosis to
follow-up
PAEDIATRICS AND CHILD HEALTH 20:3
33. Information helps decide ď
Post op radiotherapy
ďRadiotherapy indicated for patients with
positive margins and considered for those with
residual viable tumor
ďRadiation dose adjusted depending upon the
percentage necrosis of tumor and margins of
resection
36. 10/20/12 36
Osteosarcoma lesions can be purely osteolytic
(30%), purely osteoblastic (45%), or a mixture of
both. (Kesselring 1982).
Lytic Sclerotic Mixed
38. 10/20/12 38
ďCT scanning
CT scanning of the chest is more sensitive than is
plain film radiography for assessing pulmonary
metastases.
ďMRI
MRI of the primary lesion is the best method to assess
the extent of intramedullary disease as well as
associated soft-tissue masses and skip lesions. (Estrada
1995)
ďBone Scan
A bone scan should be obtained to look for skeletal
metastases or multi focal disease.
39. 10/20/12 39
Treatment
ďCurrent standard of care
1. Radiological staging
2. Biopsy to confirm diagnosis
3. Preoperative chemotherapy
4. Repeat radiological staging
(access chemo response, finalize surgical tx plan)
5. Surgical resection with wide margin
6. Reconstruction using one of many
techniques
7. Post op chemo based on preop response
41. 10/20/12 41
Chemotherapy
ďBefore the era chemotherapy osteosarcoma was usually
treated with immediate wide or radical amputation on
diagnosis.
ďThis usually treated the local disease adequately. However
80% of patients eventually died of micrometastatic
disease.
ďWith the use of modern chemotherapy protocols, the
current 5-year survival rate for osteosarcoma is
approximately 70%.
42. 10/20/12 42
Surgery
ďThe main goal of surgery is to safely and completely
remove the tumor.
ďHistorically, most patients had an amputation. Over the
past 30 years, limb-sparing procedures have become the
standard, mainly due to advances in chemotherapy and
sophisticated imaging techniques (Scully 2002).
ďLimb salvage procedures now can provide rates of local
control and long-term survival equal to amputation.
44. 10/20/12 44
Radiotherapy
ďRadiation therapy has no major role in osteosarcoma
ďRadiation therapy may be useful in some cases where the
tumor cannot be completely removed by surgery. E.g. in
pelvic bones or in the bones of the face. In these
situations, As much tumor as possible is removed, and
then radiation is given to try to kill the remaining cancer
cells. Chemotherapy may be used after radiation.
ďRadiation can also be helpful in controlling symptoms like
pain and swelling if the cancer has come back or surgery is
not possible.
45. Ewingsâ sarcoma
ď ESFTs 2nd
decade of life
ď Accounts for 4% of
childhood and
adolescent malignancies
ď One third of primary
bone tumours
ď Origin: Primordial neural
stem cell
ď Slight male
preponderance
ď âsmall round blue cell
tumors of childhoodâ
EFT
ETB 60% EOE PNET
48. ďBx âpreferably from soft tissue mass and
not from bone. If bone Bx reqd ,small
cortical window made.
ďTissue for IHC ,RT-PCR.
ďB/L iliac for BMA and Bx.
ďIHC âMic 2 [CD 99], membrane
expression,vimentin, NSE and
synaptophysin
ď Neural markers - neuron-specific
enolase, Leu-7, synaptophysin,
neurofilament, and S100.
49. Management
ďThe primary goal of treatment is local control of the
disease while, if possible, achieving salvage of the
limb and its function
ďLimb-salvage procedures a valid alternative method
of treatment to amputation in 80-85% of patients
with primary bone sarcomas.
Wafa H et alExpert Rev Anticancer Ther. 2006 Feb;6(2):239-48.
50. Why anterior chemotherapy
ďBefore the era of chemotherapy, fewer
than 10% of patients with Ewingâs
sarcoma survived despite
radiosensitivity
ďWhy systemic therapy?
Mortality within 2 yrs with distant
metastasis
Jenkin RD, Clin Radiol1966;17:97â106
51. Rx Flow ChartInduction Chemotherapy
Sx Feasible
Sx Not Feasible
CT not Effective
W/E not possible
Amputation
Definitive RTPORT
Maintenance CT
52. Information helps decide ď
Post op radiotherapy
ďRadiotherapy indicated for patients with
positive margins and considered for those with
residual viable tumor
ďRadiation dose adjusted depending upon the
percentage necrosis of tumor and margins of
resection
53. Is surgery the best modality for local control at all sites ?
?
54. ďŹ Ewingâs pelvis L
ďŹ 8 year old girl
ďŹ Involves ilium + upper acetabulum
64. Imaging
ďMRI
ď For extremity masses
ď Gives good delineation between muscle, tumor and
blood vessels
ďCT for abdominal and retroperitoneal
ďPET
ď May help determine high vs. low grade
ď May be helpful in recurrences
66. Relative risk for recurrence and survival
ďAge >50 years 1.6
ďLocal recurrence at presentation 2.0
ďMicroscopically positive margin 1.8
ďSize 5.0â10.0 cm 1.9
ďSize > 10.0 cm 1.5
ďHigh-grade 4.3
ďDeep location 2.5
ďLocal recurrence 1.5
67. Surgery
ďLimb-sparing vs amputation
ď Comparison study with post-op radiation in limb sparing
showed no difference in survival
ďAmputation still may be indicated for
neurovascular or bone involvement
68. Resection
ďArbitrary 2 cm margin if no plan for post-op
radiotherapy
ďNegative margins may be adequate for post-op
radiation therapy
ď Presence of positive margins increases local recurrence
by 10-15%
ďNo need for lymph node dissection as only 2-3%
have nodal metastasis
69. Adjuvant radiotherapy
ďSmall, low grade tumors resected with 2 cm
margins may not require radiation
ďImproves local control but not survival
ďWhether improved local control leads to
improved survival is controversial
70. Pre-op or post-op radiation?
ďSome avoid pre-op use because of increased
wound complications (although this is debatable)
ď RCT looking at wound complication rate pre-op vs post-
op radiation showed 35% vs 17%
ď Risk confined to lower extremity
ď Conclusions: pre-op may be better for upper extremity
and head & neck because of equal wound complication
risk and benefit of lower radiation doses to more vital
tissues
72. Chemotherapy
ďCan improve local control, but not survival
ďDoxorubicin and iFosfamide have response rates
of 20%
ďUse only in advanced disease
ďCombination with radiation or neoadjuvant
therapy are controversial
ďHypothermic isolated limb perfusion may be used
for palliation
73. Treatment of Recurrence
ď20-30% of STS patients will recur
ďMore common in retroperitoneal and head &
neck high grade tumors because hard to get clear
margins
ď 38% for retroperitoneal
ď 42% for head and neck
ď 5-25% for extremity
ďAfter re-resection recurrence is 32% for extremity
and much higher for visceral
75. Retroperitoneal Sarcomas
ď15% of all sarcomas
ďLiposarcoma 42% and leiomyosarcoma 26%
ďCT scan can show cystic/solid/necrotic components and relation
to surroundings
ďCXR to r/o mets, chest CT if CXR abnormal
ďBiopsy not necessary unless suspect a lymphoma or germ cell
tumor or plan preop chemo or radiation
ďEn bloc resection is standard treatment
ď bowel prep
ď assess bilateral kidney function
ď 50-80% need organ resection
ď 78% of primary lesions can be completely resected
77. Prognosis for retroperitoneal sarcomas
ď5 year survival after complete resection of 54-65%
ď Drops to 10-36% if incompletely resected
ďRecurrence occurs in 46-59% of completely
resected tumors
78. Radiation or chemotherapy for retroperitoneal
sarcomas
ďRadiation
ďGI and neuro toxicities limit delivery of sufficient
doses
ďMay improve local control
ďRecommended for use only in clinical trials given
lack of data either way
ďChemotherapy
ďUse for recurrent, unresectable or metastatic
disease
79. GIST
ďSeparate subtype of sarcoma defined by expression of
c-Kit (CD117)
ďSurgery: complete resection without local or regional
lymphadenectomy
ďVery resistant to traditional chemotherapy
ďGleevec (imantinib mesylate)
ď c-Kit is constitutively active tyrosine kinase receptor
ď Drug is tyrosine kinase inhibitor used in CML
ď Initial studies showed 54% response rates
ď Two RCTs currently looking at adjuvant treatment
114. CAUTION
C - Change in bowel or bladder habits
A - A sore that does not heal
U - Unusual bleeding or discharge
T - Thickening or lump in the breast or any part of the
body
I - Indigestion or difficulty swallowing
O - Obvious change in a wart or mole
N - Nagging cough or hoarseness
40. Breast Cancer: Stage IV
Stage IV, or metastatic, breast cancer is a lethal disease. The most common sites of metastases are soft tissue (skin or draining lymph nodes), bone, and viscera (eg, liver, lung).